Clinical outcome assessment in Multiple Sclerosis (MS) is challenging due to the diversity
and fluctuating nature of MS symptoms. Traditional clinical scales such as the EDSS are …

With the advent and widespread use of partially effective disease modifying drug therapies
for multiple sclerosis (MS), future clinical trials will undoubtedly test experimental …

OBJECTIVE: Chronic cerebrospinal venous insufficiency (CCSVI) is characterized by
combined stenoses of the principal pathways of extracranial venous drainage, including the …

Background: Interferon β-1a (IFNβ-1a, Avonex) is efficacious in relapsing forms of MS.
Studies of other IFNβ preparations in secondary progressive MS (SPMS) yielded conflicting …

While much work has concentrated on focal white matter (WM) lesions in multiple sclerosis,
there is growing evidence to suggest that normal‐appearing WM (NAWM) and grey matter …

Objective: To assess the short-term efficacy and effectiveness of a six-week energy
conservation course on fatigue impact, quality of life and self-efficacy for persons with …

Regular exercise is important for patients with multiple sclerosis (MS) to maintain their
functional ability and general health. The aim of this study was to determine whether a long …

Objective: To examine cognitive functioning in children with multiple sclerosis (MS).
Methods: The authors examined the neuropsychological profile of 37 children with a …

Objectives To calculate the percentage of participation restrictions according to disability
level in multiple sclerosis (MS), and to assess the relationship between participation …

Background: Laquinimod is a novel immunomodulatory substance developed as an orally
available disease modifying treatment in multiple sclerosis (MS). The purpose of this study …